Molecular changes consistent with increased proliferation and invasion are common in rectal cancer

Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Hughes, Rebecca [verfasserIn] Parry, James [verfasserIn] Beynon, John [verfasserIn] Jenkins, Gareth [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2011

Schlagwörter:	Rectal cancer Molecular changes Neoadjuvant therapy

Übergeordnetes Werk:	Enthalten in: Revista de oncología - Barcelona : Doyma, 2000, 13(2011), 10 vom: Okt., Seite 753-759
Übergeordnetes Werk:	volume:13 ; year:2011 ; number:10 ; month:10 ; pages:753-759

Links:	Volltext

DOI / URN:	10.1007/s12094-011-0728-4

Katalog-ID:	SPR024256722

Internformat


LEADER	01000caa a22002652 4500
001	SPR024256722
003	DE-627
005	20230519111106.0
007	cr uuu---uuuuu
008	201006s2011 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s12094-011-0728-4 \|2 doi
035			\|a (DE-627)SPR024256722
035			\|a (SPR)s12094-011-0728-4-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q ASE
100	1		\|a Hughes, Rebecca \|e verfasserin \|4 aut
245	1	0	\|a Molecular changes consistent with increased proliferation and invasion are common in rectal cancer
264		1	\|c 2011
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer.
650		4	\|a Rectal cancer \|7 (dpeaa)DE-He213
650		4	\|a Molecular changes \|7 (dpeaa)DE-He213
650		4	\|a Neoadjuvant therapy \|7 (dpeaa)DE-He213
700	1		\|a Parry, James \|e verfasserin \|4 aut
700	1		\|a Beynon, John \|e verfasserin \|4 aut
700	1		\|a Jenkins, Gareth \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Revista de oncología \|d Barcelona : Doyma, 2000 \|g 13(2011), 10 vom: Okt., Seite 753-759 \|w (DE-627)385985452 \|w (DE-600)2143451-7 \|x 1578-195X \|7 nnns
773	1	8	\|g volume:13 \|g year:2011 \|g number:10 \|g month:10 \|g pages:753-759
856	4	0	\|u https://dx.doi.org/10.1007/s12094-011-0728-4 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_120
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_224
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
951			\|a AR
952			\|d 13 \|j 2011 \|e 10 \|c 10 \|h 753-759

Indexfelder

author_variant	r h rh j p jp j b jb g j gj
matchkey_str	article:1578195X:2011----::oeuacagsossetihnraepoieainnivso
hierarchy_sort_str	2011
publishDate	2011
allfields	10.1007/s12094-011-0728-4 doi (DE-627)SPR024256722 (SPR)s12094-011-0728-4-e DE-627 ger DE-627 rakwb eng 610 ASE Hughes, Rebecca verfasserin aut Molecular changes consistent with increased proliferation and invasion are common in rectal cancer 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer. Rectal cancer (dpeaa)DE-He213 Molecular changes (dpeaa)DE-He213 Neoadjuvant therapy (dpeaa)DE-He213 Parry, James verfasserin aut Beynon, John verfasserin aut Jenkins, Gareth verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 13(2011), 10 vom: Okt., Seite 753-759 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:13 year:2011 number:10 month:10 pages:753-759 https://dx.doi.org/10.1007/s12094-011-0728-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 13 2011 10 10 753-759
spelling	10.1007/s12094-011-0728-4 doi (DE-627)SPR024256722 (SPR)s12094-011-0728-4-e DE-627 ger DE-627 rakwb eng 610 ASE Hughes, Rebecca verfasserin aut Molecular changes consistent with increased proliferation and invasion are common in rectal cancer 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer. Rectal cancer (dpeaa)DE-He213 Molecular changes (dpeaa)DE-He213 Neoadjuvant therapy (dpeaa)DE-He213 Parry, James verfasserin aut Beynon, John verfasserin aut Jenkins, Gareth verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 13(2011), 10 vom: Okt., Seite 753-759 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:13 year:2011 number:10 month:10 pages:753-759 https://dx.doi.org/10.1007/s12094-011-0728-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 13 2011 10 10 753-759
allfields_unstemmed	10.1007/s12094-011-0728-4 doi (DE-627)SPR024256722 (SPR)s12094-011-0728-4-e DE-627 ger DE-627 rakwb eng 610 ASE Hughes, Rebecca verfasserin aut Molecular changes consistent with increased proliferation and invasion are common in rectal cancer 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer. Rectal cancer (dpeaa)DE-He213 Molecular changes (dpeaa)DE-He213 Neoadjuvant therapy (dpeaa)DE-He213 Parry, James verfasserin aut Beynon, John verfasserin aut Jenkins, Gareth verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 13(2011), 10 vom: Okt., Seite 753-759 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:13 year:2011 number:10 month:10 pages:753-759 https://dx.doi.org/10.1007/s12094-011-0728-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 13 2011 10 10 753-759
allfieldsGer	10.1007/s12094-011-0728-4 doi (DE-627)SPR024256722 (SPR)s12094-011-0728-4-e DE-627 ger DE-627 rakwb eng 610 ASE Hughes, Rebecca verfasserin aut Molecular changes consistent with increased proliferation and invasion are common in rectal cancer 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer. Rectal cancer (dpeaa)DE-He213 Molecular changes (dpeaa)DE-He213 Neoadjuvant therapy (dpeaa)DE-He213 Parry, James verfasserin aut Beynon, John verfasserin aut Jenkins, Gareth verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 13(2011), 10 vom: Okt., Seite 753-759 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:13 year:2011 number:10 month:10 pages:753-759 https://dx.doi.org/10.1007/s12094-011-0728-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 13 2011 10 10 753-759
allfieldsSound	10.1007/s12094-011-0728-4 doi (DE-627)SPR024256722 (SPR)s12094-011-0728-4-e DE-627 ger DE-627 rakwb eng 610 ASE Hughes, Rebecca verfasserin aut Molecular changes consistent with increased proliferation and invasion are common in rectal cancer 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer. Rectal cancer (dpeaa)DE-He213 Molecular changes (dpeaa)DE-He213 Neoadjuvant therapy (dpeaa)DE-He213 Parry, James verfasserin aut Beynon, John verfasserin aut Jenkins, Gareth verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 13(2011), 10 vom: Okt., Seite 753-759 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:13 year:2011 number:10 month:10 pages:753-759 https://dx.doi.org/10.1007/s12094-011-0728-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 13 2011 10 10 753-759
language	English
source	Enthalten in Revista de oncología 13(2011), 10 vom: Okt., Seite 753-759 volume:13 year:2011 number:10 month:10 pages:753-759
sourceStr	Enthalten in Revista de oncología 13(2011), 10 vom: Okt., Seite 753-759 volume:13 year:2011 number:10 month:10 pages:753-759
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Rectal cancer Molecular changes Neoadjuvant therapy
dewey-raw	610
isfreeaccess_bool	false
container_title	Revista de oncología
authorswithroles_txt_mv	Hughes, Rebecca @@aut@@ Parry, James @@aut@@ Beynon, John @@aut@@ Jenkins, Gareth @@aut@@
publishDateDaySort_date	2011-10-01T00:00:00Z
hierarchy_top_id	385985452
dewey-sort	3610
id	SPR024256722
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR024256722</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519111106.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2011 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-011-0728-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR024256722</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-011-0728-4-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hughes, Rebecca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular changes consistent with increased proliferation and invasion are common in rectal cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rectal cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular changes</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoadjuvant therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parry, James</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Beynon, John</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jenkins, Gareth</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">13(2011), 10 vom: Okt., Seite 753-759</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2011</subfield><subfield code="g">number:10</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:753-759</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-011-0728-4</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2011</subfield><subfield code="e">10</subfield><subfield code="c">10</subfield><subfield code="h">753-759</subfield></datafield></record></collection>
author	Hughes, Rebecca
spellingShingle	Hughes, Rebecca ddc 610 misc Rectal cancer misc Molecular changes misc Neoadjuvant therapy Molecular changes consistent with increased proliferation and invasion are common in rectal cancer
authorStr	Hughes, Rebecca
ppnlink_with_tag_str_mv	@@773@@(DE-627)385985452
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1578-195X
topic_title	610 ASE Molecular changes consistent with increased proliferation and invasion are common in rectal cancer Rectal cancer (dpeaa)DE-He213 Molecular changes (dpeaa)DE-He213 Neoadjuvant therapy (dpeaa)DE-He213
topic	ddc 610 misc Rectal cancer misc Molecular changes misc Neoadjuvant therapy
topic_unstemmed	ddc 610 misc Rectal cancer misc Molecular changes misc Neoadjuvant therapy
topic_browse	ddc 610 misc Rectal cancer misc Molecular changes misc Neoadjuvant therapy
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Revista de oncología
hierarchy_parent_id	385985452
dewey-tens	610 - Medicine & health
hierarchy_top_title	Revista de oncología
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)385985452 (DE-600)2143451-7
title	Molecular changes consistent with increased proliferation and invasion are common in rectal cancer
ctrlnum	(DE-627)SPR024256722 (SPR)s12094-011-0728-4-e
title_full	Molecular changes consistent with increased proliferation and invasion are common in rectal cancer
author_sort	Hughes, Rebecca
journal	Revista de oncología
journalStr	Revista de oncología
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2011
contenttype_str_mv	txt
container_start_page	753
author_browse	Hughes, Rebecca Parry, James Beynon, John Jenkins, Gareth
container_volume	13
class	610 ASE
format_se	Elektronische Aufsätze
author-letter	Hughes, Rebecca
doi_str_mv	10.1007/s12094-011-0728-4
dewey-full	610
author2-role	verfasserin
title_sort	molecular changes consistent with increased proliferation and invasion are common in rectal cancer
title_auth	Molecular changes consistent with increased proliferation and invasion are common in rectal cancer
abstract	Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer.
abstractGer	Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer.
abstract_unstemmed	Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702
container_issue	10
title_short	Molecular changes consistent with increased proliferation and invasion are common in rectal cancer
url	https://dx.doi.org/10.1007/s12094-011-0728-4
remote_bool	true
author2	Parry, James Beynon, John Jenkins, Gareth
author2Str	Parry, James Beynon, John Jenkins, Gareth
ppnlink	385985452
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s12094-011-0728-4
up_date	2024-07-04T00:11:19.406Z
_version_	1803605119504220160
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR024256722</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519111106.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2011 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-011-0728-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR024256722</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-011-0728-4-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hughes, Rebecca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular changes consistent with increased proliferation and invasion are common in rectal cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rectal cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular changes</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoadjuvant therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parry, James</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Beynon, John</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jenkins, Gareth</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">13(2011), 10 vom: Okt., Seite 753-759</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2011</subfield><subfield code="g">number:10</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:753-759</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-011-0728-4</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2011</subfield><subfield code="e">10</subfield><subfield code="c">10</subfield><subfield code="h">753-759</subfield></datafield></record></collection>
score	7.400074

Nicht das Richtige dabei?

Schreiben Sie uns!

Molecular changes consistent with increased proliferation and invasion are common in rectal cancer

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?